Menu
Search
|

Menu

Close
X

Biospecifics Technologies Corp BSTC.OQ (NASDAQ Stock Exchange Global Market)

38.52 USD
-0.51 (-1.31%)
As of 3:59 PM EST
chart
Previous Close 39.03
Open 38.87
Volume 14,483
3m Avg Volume 7,459
Today’s High 39.05
Today’s Low 38.12
52 Week High 58.36
52 Week Low 38.12
Shares Outstanding (mil) 7.19
Market Capitalization (mil) 280.60
Forward P/E 24.57
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
21
FY16
26
FY15
23
EPS (USD)
FY17
1.189
FY16
1.562
FY15
1.322
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
24.57
35.64
Price to Sales (TTM)
vs sector
10.25
8.67
Price to Book (MRQ)
vs sector
4.32
5.21
Price to Cash Flow (TTM)
vs sector
20.47
26.03
Total Debt to Equity (MRQ)
vs sector
0.00
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
17.83
13.57
Return on Equity (TTM)
vs sector
19.67
15.19

EXECUTIVE LEADERSHIP

Thomas Wegman
President, Principal Executive Officer, Principal Financial Officer, Director, Since 2009
Salary: $350,000.00
Bonus: --
Mark Wegman
Director, Since 2007
Salary: --
Bonus: --
Toby Wegman
Director, Since 2007
Salary: --
Bonus: --
Jennifer Chao
Independent Director, Since 2015
Salary: --
Bonus: --
Paul Gitman
Independent Director, Since 1990
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

35 WILBUR ST
LYNBROOK   NY   11563-2358

Phone: +1516.5937000

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

SPONSORED STORIES